CliffBio
small molecule

JUXTAPID

LOMITAPIDE MESYLATE

Loss of exclusivityJuly 2041latest FDA-listed patent expiry
CompanyCHIESI FARMACEUTICI SPA

Drug detail

Brand nameJUXTAPID
Active ingredientLOMITAPIDE MESYLATE
StrengthEQ 10MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2012
Marketing statusRX

Listed patents

PatentExpiresType
12472172July 2041use U-4438
7932268August 2027use U-1316

Regulatory exclusivity

CodeExpires
NPPFebruary 2029

More from CHIESI FARMACEUTICI SPA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

JUXTAPID patent cliff — loss of exclusivity July 2041 | CliffBio